FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:TRAF2-CAPN2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: TRAF2-CAPN2
FusionPDB ID: 93644
FusionGDB2.0 ID: 93644
HgeneTgene
Gene symbol

TRAF2

CAPN2

Gene ID

10010

824

Gene nameTRAF family member associated NFKB activatorcalpain 2
SynonymsI-TRAF|ITRAF|TRAF2CANP2|CANPL2|CANPml|mCANP
Cytomap

2q24.2

1q41

Type of geneprotein-codingprotein-coding
DescriptionTRAF family member-associated NF-kappa-B activatorTRAF-interacting proteincalpain-2 catalytic subunitCANP 2M-calpaincalcium-activated neutral proteinase 2calpain 2, (m/II) large subunitcalpain 2, large [catalytic] subunitcalpain 2, large subunitcalpain M-typecalpain, large polypeptide L2millimolar-calpain
Modification date2020031320200313
UniProtAcc

TNIK

Main function of 5'-partner protein: 1360

P17655

Main function of 5'-partner protein: FUNCTION: Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction. Proteolytically cleaves MYOC at 'Arg-226' (PubMed:17650508). Proteolytically cleaves CPEB3 following neuronal stimulation which abolishes CPEB3 translational repressor activity, leading to translation of CPEB3 target mRNAs (By similarity). {ECO:0000250|UniProtKB:O08529, ECO:0000269|PubMed:17650508}.
Ensembl transtripts involved in fusion geneENST idsENST00000247668, ENST00000359662, 
ENST00000536468, ENST00000482854, 
ENST00000474026, ENST00000295006, 
ENST00000433674, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score7 X 6 X 6=25211 X 7 X 7=539
# samples 711
** MAII scorelog2(7/252*10)=-1.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(11/539*10)=-2.29278174922785
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: TRAF2 [Title/Abstract] AND CAPN2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: TRAF2 [Title/Abstract] AND CAPN2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)TRAF2(139794124)-CAPN2(223946971), # samples:1
Anticipated loss of major functional domain due to fusion event.TRAF2-CAPN2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TRAF2-CAPN2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
TRAF2-CAPN2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
TRAF2-CAPN2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneCAPN2

GO:0051603

proteolysis involved in cellular protein catabolic process

12150984



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr9:139794124/chr1:223946971)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across TRAF2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CAPN2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000536468TRAF2chr9139794124+ENST00000433674CAPN2chr1223946971+23854401491225358
ENST00000536468TRAF2chr9139794124+ENST00000295006CAPN2chr1223946971+23874401491225358
ENST00000247668TRAF2chr9139794124+ENST00000433674CAPN2chr1223946971+2264319281104358
ENST00000247668TRAF2chr9139794124+ENST00000295006CAPN2chr1223946971+2266319281104358
ENST00000359662TRAF2chr9139794124+ENST00000433674CAPN2chr1223946971+2257312211097358
ENST00000359662TRAF2chr9139794124+ENST00000295006CAPN2chr1223946971+2259312211097358

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000536468ENST00000433674TRAF2chr9139794124+CAPN2chr1223946971+0.0006257560.9993742
ENST00000536468ENST00000295006TRAF2chr9139794124+CAPN2chr1223946971+0.0006308140.9993692
ENST00000247668ENST00000433674TRAF2chr9139794124+CAPN2chr1223946971+0.000436310.99956363
ENST00000247668ENST00000295006TRAF2chr9139794124+CAPN2chr1223946971+0.0004392470.9995608
ENST00000359662ENST00000433674TRAF2chr9139794124+CAPN2chr1223946971+0.0004459570.999554
ENST00000359662ENST00000295006TRAF2chr9139794124+CAPN2chr1223946971+0.0004506090.9995493

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for TRAF2-CAPN2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
TRAF2chr9139794124CAPN2chr122394697131297IYEEGISILESSSLSGQTNIHLSKNF
TRAF2chr9139794124CAPN2chr122394697131997IYEEGISILESSSLSGQTNIHLSKNF
TRAF2chr9139794124CAPN2chr122394697144097IYEEGISILESSSLSGQTNIHLSKNF

Top

Potential FusionNeoAntigen Information of TRAF2-CAPN2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TRAF2-CAPN2_139794124_223946971.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TRAF2-CAPN2chr9139794124chr1223946971319HLA-B15:17ISILESSSL0.99160.7612514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C03:07ISILESSSL0.99970.9761514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C03:19ISILESSSL0.99970.9897514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C03:08ISILESSSL0.99970.8943514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C15:06ISILESSSL0.99920.8779514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C15:06SSLSGQTNI0.99830.75531120
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C08:04ISILESSSL0.99350.9138514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C08:13ISILESSSL0.99350.9138514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C01:17ISILESSSL0.95320.9241514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C08:03ISILESSSL0.94720.969514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C01:30ISILESSSL0.70270.9556514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C03:04ISILESSSL0.99980.9889514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C03:03ISILESSSL0.99980.9889514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C03:17ISILESSSL0.99950.9664514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C03:05ISILESSSL0.99950.918514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C03:02ISILESSSL0.99910.9631514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C15:05ISILESSSL0.99910.8629514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C15:02SSLSGQTNI0.9990.54411120
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C15:05SSLSGQTNI0.99870.66091120
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C03:06ISILESSSL0.99010.9886514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C16:01ISILESSSL0.96690.9675514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C01:02ISILESSSL0.95850.9193514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C16:02ISILESSSL0.94980.9757514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C08:01ISILESSSL0.94720.969514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-B15:30ISILESSSL0.94190.6076514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C01:03ISILESSSL0.93280.9218514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-B35:13ISILESSSL0.83430.8365514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-C17:01ISILESSSL0.68070.8447514
TRAF2-CAPN2chr9139794124chr1223946971319HLA-B07:13ISILESSSL0.50840.7609514

Top

Potential FusionNeoAntigen Information of TRAF2-CAPN2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
TRAF2-CAPN2_139794124_223946971.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0101EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0102EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0102YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0105EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0107EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0111EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0119EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0123EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0125EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0127EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-0131EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1201EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1201YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1203EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1203YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1205EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1205YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1206EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1206YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1207EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1207YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1208EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1208YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1210EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1210YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1211EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1211YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1212EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1212YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1213EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1213YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1214EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1214YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1215EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1215YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1217EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1217YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1218EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1218YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1219EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1219YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1220EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1221EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1221YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1222EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1223EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1223YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1410EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1431EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1501EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1504EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1505EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1506EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1507EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1507YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1509EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1512EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1513EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1516EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1520EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1521EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1522EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1523EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1524EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1525EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1527EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1528EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1532EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1533EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1534EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1534YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1535EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1536EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1537EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1540EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1541EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1542EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1543EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1545EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1546EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1548EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1548YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1549EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1601EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1602EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1603EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1605EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1607EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1608EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1611EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1612EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1614EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1615EEGISILESSSLSGQ217
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1615YEEGISILESSSLSG116
TRAF2-CAPN2chr9139794124chr1223946971319DRB1-1616EEGISILESSSLSGQ217

Top

Fusion breakpoint peptide structures of TRAF2-CAPN2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8650SILESSSLSGQTNITRAF2CAPN2chr9139794124chr1223946971319

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of TRAF2-CAPN2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN8650SILESSSLSGQTNI-7.9962-8.1096
HLA-B14:023BVN8650SILESSSLSGQTNI-5.70842-6.74372
HLA-B52:013W398650SILESSSLSGQTNI-6.83737-6.95077
HLA-B52:013W398650SILESSSLSGQTNI-4.4836-5.5189
HLA-A11:014UQ28650SILESSSLSGQTNI-10.0067-10.1201
HLA-A11:014UQ28650SILESSSLSGQTNI-9.03915-10.0745
HLA-A24:025HGA8650SILESSSLSGQTNI-6.56204-6.67544
HLA-A24:025HGA8650SILESSSLSGQTNI-5.42271-6.45801
HLA-B44:053DX88650SILESSSLSGQTNI-7.85648-8.89178
HLA-B44:053DX88650SILESSSLSGQTNI-5.3978-5.5112
HLA-A02:016TDR8650SILESSSLSGQTNI-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of TRAF2-CAPN2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
TRAF2-CAPN2chr9139794124chr12239469711120SSLSGQTNIAGTTCGTTAAGTGGGCAGACCAACATC
TRAF2-CAPN2chr9139794124chr1223946971514ISILESSSLATTTCTATTTTAGAAAGCAGTTCGTTA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
TRAF2-CAPN2chr9139794124chr1223946971116YEEGISILESSSLSGTATGAAGAAGGCATTTCTATTTTAGAAAGCAGTTCGTTAAGTGGG
TRAF2-CAPN2chr9139794124chr1223946971217EEGISILESSSLSGQGAAGAAGGCATTTCTATTTTAGAAAGCAGTTCGTTAAGTGGGCAG

Top

Information of the samples that have these potential fusion neoantigens of TRAF2-CAPN2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADTRAF2-CAPN2chr9139794124ENST00000247668chr1223946971ENST00000295006TCGA-BR-A4IZ

Top

Potential target of CAR-T therapy development for TRAF2-CAPN2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to TRAF2-CAPN2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to TRAF2-CAPN2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource